01—Abstract
Summary
Summary of the 8-K filed December 10, 2025. Cited figures are marked; the original filing is the authoritative source.
Axon Enterprise, Inc. (AXON) has announced its entry into privately negotiated Exchange Agreements with certain holders of its 0.50%a convertible senior notes due 2027.
These agreements will facilitate the exchange of approximately $177.9 millionb in aggregate principal amount of these notes for a combination of cash and newly issued Axon common stock. The exact number of shares to be issued will be determined based on a one-day volume-weighted average price (VWAP) on December 10, 2025, with an estimated issuance of 468,000 shares assuming a hypothetical VWAP of $550.95. This transaction is expected to reduce the outstanding principal amount of the convertible notes to approximately $100.1 million upon closing, anticipated around December 16, 2025.
The company is utilizing an exemption under Section 4(a)(2) of the Securities Act for the issuance of these shares, requiring holders to be accredited and qualified institutional buyers. Investors should note that the unwinding of hedging positions by some noteholders could potentially lead to increased volatility in Axon's stock price around the closing date.
02—Key points
Key Highlights
- Axon is exchanging approximately $177.9 million of its 0.50% convertible senior notes due 2027 for cash and common stock.
- The exchange is expected to reduce the outstanding principal of these notes to roughly $100.1 million.
- Approximately 468,000 shares of common stock are anticipated to be issued, based on a projected $550.95 per share average price.
- The issuance of shares is being conducted under an exemption from registration requirements (Section 4(a)(2) of the Securities Act).
- Holders participating in the exchange are required to be accredited and qualified institutional buyers.
- Unwinding of hedging strategies by some noteholders could significantly impact Axon's stock price around the closing date.
- The closing of these exchanges is expected to occur on or about December 16, 2025.
03—Questions
Frequently Asked Questions
What is the primary purpose of these Exchange Agreements?
The primary purpose is to reduce Axon's outstanding convertible senior notes by approximately $177.9 million and, in exchange, issue a combination of cash and Axon common stock to the noteholders. This effectively deleverages the company's balance sheet concerning these specific notes.
How will the number of shares issued be determined?
The number of shares will be determined by the volume-weighted average price (VWAP) of Axon's common stock over a one-day averaging period on December 10, 2025. The filing provides an estimate of 468,000 shares based on a hypothetical VWAP of $550.95.
What is the potential impact on Axon's stock price?
The unwinding of hedging strategies by noteholders who have hedged their equity exposure could lead to substantial purchases or sales of Axon's common stock. This activity may increase, or reduce the size of any decrease in, the market price of Axon's stock, though the company cannot predict the magnitude or overall effect.
Are these shares being issued through a public offering?
No, the shares are being issued pursuant to privately negotiated agreements under the exemption provided by Section 4(a)(2) of the Securities Act. This means the shares have not been registered with the SEC and are being issued only to institutional accredited investors and qualified institutional buyers.
04—Continue